TG Therapeutics FY2025 EPS Estimate Raised by HC Wainwright

TG Therapeutics, Inc. (NASDAQ:TGTX) – Stock analysts at HC Wainwright upped their FY2025 earnings per share estimates for TG Therapeutics in a research note issued to investors on Wednesday, January 15th. HC Wainwright analyst E. White now forecasts that the biopharmaceutical company will post earnings of $1.26 per share for the year, up from their previous forecast of $1.17. HC Wainwright currently has a “Buy” rating and a $55.00 price target on the stock. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.07 per share.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The business had revenue of $83.90 million during the quarter, compared to analysts’ expectations of $81.68 million. During the same period in the prior year, the company earned $0.73 earnings per share. The firm’s quarterly revenue was down 49.4% compared to the same quarter last year.

TGTX has been the topic of several other research reports. JPMorgan Chase & Co. upped their price target on TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research note on Monday, November 25th. StockNews.com raised TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, January 7th. The Goldman Sachs Group lifted their price target on TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Finally, TD Cowen assumed coverage on shares of TG Therapeutics in a research report on Tuesday, October 29th. They set a “buy” rating and a $50.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $40.67.

TG Therapeutics Price Performance

Shares of TGTX opened at $29.14 on Thursday. The firm’s 50-day simple moving average is $31.69 and its two-hundred day simple moving average is $25.63. TG Therapeutics has a fifty-two week low of $12.84 and a fifty-two week high of $36.84. The stock has a market cap of $4.54 billion, a PE ratio of -291.37 and a beta of 2.24. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59.

Hedge Funds Weigh In On TG Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Victory Capital Management Inc. lifted its holdings in TG Therapeutics by 24.6% in the second quarter. Victory Capital Management Inc. now owns 26,212 shares of the biopharmaceutical company’s stock valued at $466,000 after acquiring an additional 5,169 shares during the period. State of New Jersey Common Pension Fund D purchased a new stake in shares of TG Therapeutics during the 2nd quarter valued at about $2,022,000. XTX Topco Ltd bought a new position in shares of TG Therapeutics in the 2nd quarter worth approximately $395,000. Hood River Capital Management LLC boosted its holdings in shares of TG Therapeutics by 6.7% in the second quarter. Hood River Capital Management LLC now owns 1,572,929 shares of the biopharmaceutical company’s stock worth $27,982,000 after buying an additional 98,892 shares during the last quarter. Finally, Marshall Wace LLP bought a new stake in TG Therapeutics during the second quarter valued at approximately $36,501,000. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at TG Therapeutics

In related news, Director Sagar Lonial sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $30.44, for a total value of $152,200.00. Following the sale, the director now owns 100,195 shares in the company, valued at approximately $3,049,935.80. This trade represents a 4.75 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Sean A. Power sold 10,021 shares of TG Therapeutics stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $28.53, for a total transaction of $285,899.13. Following the completion of the sale, the chief financial officer now directly owns 660,611 shares of the company’s stock, valued at approximately $18,847,231.83. This trade represents a 1.49 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 26,358 shares of company stock worth $781,497 over the last quarter. 10.50% of the stock is currently owned by insiders.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.